|
1
|
Agate L, Lorusso L and Elisei R: New and
old knowledge on differentiated thyroid cancer epidemiology and
risk factors. J Endocrinol Invest. 35(Suppl): 3–9. 2012.PubMed/NCBI
|
|
2
|
National Cancer Institute, . Surveillance
Epidemiology and End Results Program: SEER stat fact sheets:
Thyroid cancer. http://seer.cancer.gov/statfacts/html/thyro.html#incidence-mortality15th–
June. 2013
|
|
3
|
Cooper DS, Doherty GM, Haugen BR, et al:
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid
Nodules and Differentiated Thyroid Cancer: Revised American Thyroid
Association management guidelines for patients with thyroid nodules
and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brose M, Nutting C, Jarzab B, et al:
Sorafenib in locally advanced or metastatic patients with
radioactive iodine-refractory differentiated thyroid cancer: The
phase III DECISION trial. J Clin Oncol. 31(Suppl): Abstract 4.
2013.
|
|
5
|
DeSantis CE, Lin CC, Mariotto AB, et al:
Cancer treatment and survivorship statistics, 2014. CA Cancer J
Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dohán O, De la Vieja A, Paroder V, et al:
The sodium/iodide symporter (NIS): characterization, regulation and
medical significance. Endocr Rev. 24:48–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schlumberger MJ: Diagnostic follow-up of
well-differentiated thyroid carcinoma: historical perspective and
current status. J Endocrinol Invest. 22(Suppl): 3–7.
1999.PubMed/NCBI
|
|
8
|
Durante C, Haddy N, Baudin E, et al:
Long-term outcome of 444 patients with distant metastases from
papillary and follicular thyroid carcinoma: benefits and limits of
radioiodine therapy. J Clin Endocrinol Metab. 91:2892–2899. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perez CA, Santos ES, Arango BA, Raez LE
and Cohen EE: Novel molecular targeted therapies for refractory
thyroid cancer. Head Neck. 34:736–745. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baudin E and Schlumberger M: New
therapeutic approaches for metastatic thyroid carcinoma. Lancet
Oncol. 8:148–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nixon IJ, Shaha AR and Tuttle MR: Targeted
therapy in thyroid cancer. Curr Opin Otolaryngol Head Neck Surg.
21:130–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antonelli A, Fallahi P, Ferrari SM, et al:
New targeted therapies for thyroid cancer. Curr Genomics.
12:626–631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Omur O and Baran Y: An update on molecular
biology of thyroid cancers. Crit Rev Oncol Hematol. 90:233–252.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barollo S, Bertazza L, Baldini E, et al:
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell
lines deeply impact on proliferation and MAPK and PI3K/Akt
signaling pathways. Invest New Drugs. 32:626–635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel KN and Shaha AR: Poorly
differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck
Surg. 22:121–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sherman SI: Targeted therapy of thyroid
cancer. Biochem Pharmacol. 80:592–601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kebebew E, Weng J, Bauer J, et al: The
prevalence and prognostic value of BRAF mutation in thyroid cancer.
Ann Surg. 246:466–470; discussion 470–461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nikiforova MN, Lynch RA, Biddinger PW, et
al: RAS point mutations and PAX8-PPAR gamma rearrangement in
thyroid tumors: evidence for distinct molecular pathways in thyroid
follicular carcinoma. J Clin Endocrinol Metab. 88:2318–2326. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vasko V, Ferrand M, Di Cristofaro J,
Carayon P, Henry JF and de Micco C: Specific pattern of RAS
oncogene mutations in follicular thyroid tumors. J Clin Endocrinol
Metab. 88:2745–2752. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Castellone MD and Santoro M: Dysregulated
RET signaling in thyroid cancer. Endocrinol Metab Clin North Am.
37:363–374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherman SI: Early clinical studies of
novel therapies for thyroid cancers. Endocrinol Metab Clin North
Am. 37:511–524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen EE, Needles BM, Cullen KJ, et al:
Phase 2 study of sunitinib in refractory thyroid cancer. In: ASCO
Meeting Abstracts. 26. pp. 60252008;
|
|
24
|
Carr LL, Mankoff DA, Goulart BH, et al:
Phase II study of daily sunitinib in FDG-PET-positive,
iodine-refractory differentiated thyroid cancer and metastatic
medullary carcinoma of the thyroid with functional imaging
correlation. Clin Cancer Res. 16:5260–5268. 2010. View Article : Google Scholar : PubMed/NCBI
|
